Invion

Invion Pre-Tax Margin

The Pre-Tax Profit Margin of Invion (IVX.AX) as of Oct 21, 2026 is -1,461.90 %. In the previous year, Pre-Tax Profit Margin was -152.34 % — a change of 859.64% (lower).

Pre-Tax Margin

-1,461.90 %

YoY

859.64%

Last updated:

Pre-Tax Profit Margin of Invion is 2026 -1,461.90 % . Pre-Tax Profit Margin of Invion was 2025 -152.34 % . It decreases by 859.64% lower compared to the previous year.

The Invion Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-125.59 AUD
Jan 1, 2019
-65.59 AUD
Jan 1, 2020
-27.44 AUD
Jan 1, 2021
-63.65 AUD
Jan 1, 2022
-68.09 AUD
Jan 1, 2023
-39.34 AUD
Jan 1, 2024
-152.34 AUD
Jan 1, 2026
-1,461.90 AUD
The Invion Pre-Tax Margin history
YEARPre-Tax MarginYoY
-1,461.90 %+859.64%
-152.34 %+287.23%
-39.34 %-42.22%
-68.09 %+6.98%
-63.65 %+131.98%
-27.44 %-58.17%
-65.59 %-47.78%
-125.59 %-97.13%
-4,381.44 %-39.92%
-7,292.52 %+97.73%
-3,688.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Pre-Tax Profit Margin of Invion is -1,461.90 % in 2026.

Pre-Tax Profit Margin of Invion changed from -152.34 % to -1,461.90 %, representing a 859.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Invion since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Invion

All Key Metrics — Invion